Company Encyclopedia
View More
name
SPDR S&P Biotech
XBI.US
News
View More

Norges Bank Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO

Norges Bank acquired 1,956,654 shares of BridgeBio Pharma, valued at $84,488,000, in the second quarter, owning 1.02% of the company. Other investors also adjusted their stakes. BridgeBio's stock opened at $74.76, with a market cap of $14.41 billion. Analysts have given the stock a "Moderate Buy" rating with a consensus price target of $74.37. Recent insider trading includes sales by Director Frank Mccormick and CEO Neil Kumar.

Market Beat·
US
BBIO
+0.82%
Market Beat·
US
BBIO
+0.82%

AlphaFold Powers Engineering of Resilient Crops

Scientists at Michigan State University are using Google DeepMind's AlphaFold to engineer crops that can withstand extreme heat, addressing food security amid climate change. By predicting the structure of the enzyme glycerate kinase (GLYK), researchers have developed hybrid enzymes with enhanced heat stability. This breakthrough could lead to resilient crops, transforming agricultural biotechnology and ensuring stable food supplies in a warming world.

StartupHub·
US
GOOG
-0.70%
US
GOOGL
-0.63%
US
GGLS
+0.60%
StartupHub·
US
GOOG
-0.70%
US
GOOGL
-0.63%
US
GGLS
+0.60%

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

marketscreener·
US
MDGL
+1.09%
marketscreener·
US
MDGL
+1.09%

Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM]

Lewis William H, Chairman of Insmed Inc, filed a Form 144 with the SEC to sell 10,699 shares on December 4, 2025, through Merrill Lynch & Co Inc. The sale is executed under a prearranged trading plan (10b5-1).

Reuters·
US
INSM
-0.84%
Reuters·
US
INSM
-0.84%

CEO Sibold Files To Sell 2,400 Of Madrigal Pharmaceuticals Inc [MDGL]

CEO Sibold William John of Madrigal Pharmaceuticals Inc filed a Form 144 with the SEC to sell 2,400 restricted shares on December 4, 2025. The sale will be managed by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing the owner to sell within 90 days of filing. The Washington Service offers insider trading analysis and data services.

Reuters·
US
MDGL
+1.09%
Reuters·
US
MDGL
+1.09%
Posts
View More

Under the pressure of interest rate cuts, small-cap stocks like $SPDR S&P Biotech(XBI.US) are rising much faster than large-cap stocks like $Alphabet(GOOGL.US)😂

  • 0

The impact of interest rate cuts on small and mid-cap biotech stocks in the US market is immediate$Direxion S&P Biotech Bull 3X(LABU.US)$SPDR S&P Biotech(XBI.US)

  • 0

Adjusting the portfolio again, cutting $AMD(AMD.US) in half. Chasing some $SPDR S&P Biotech(XBI.US)$Direxion S&P Biotech Bull 3X(LABU.US), waiting for the market to continue trading on rate cut and re...

  • 0

There's already a crazy trend for 15/21 years. The funds from high-position profit-taking are sitting idle, afraid of missing out, and need to find 1-2 relatively low positions for defensive counterat.........

© 2025 Longbridge｜Disclaimer